Published 19 December 2024

This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments:

• Economic assessment: Economic evaluation (EE), Budget Impact Analysis (BIA) and Household Financial Impact (HFI) Analysis
• ELSHI assessment: Scoping review of ELSHI evidence (and systematic review and primary data collection, if deemed necessary)

The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 3 Call [FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments]

The following are the health technology topics for economic and ELSHI assessments to be funded under this Call for Capsule Proposals:

HTA Topics for Economic Assessment

For Cost-Effectiveness/Utility Analysis (CEA/CUA) + Budget Impact Analysis (BIA) + Household
Financial Impact (HFI) Analysis:

1. Ranibizumab, Aflibercept and Dexamethasone as first-line treatment for Diabetic Macular Edema (DME)
2. Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO)
3. Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 1 Diabetes Mellitus (T1DM) patients on basal insulins (i.e., neutral protamine Hagedorn (NPH) or long-acting insulins [LAIs])
4. Rapid-acting Insulin Analogs (insulin aspart, insulin lispro, insulin glulisine) compared with regular insulin among Type 2 Diabetes Mellitus (T2DM) patients on non-insulin medications or basal insulins with or without other medications
5. Ivabradine in addition to standard of care (SOC) (i.e., beta blockers) in comparison to SOC alone for adult patients aged 19 years old and above with chronic heart failure and with chronic stable angina or, with resting heart rate (HR) > 70 beats per minute (bpm) who are in sinus rhythm, despite being on optimized guideline-directed medical therapy (GDMT), or when GDMT is contraindicated
6. Ticagrelor 60 mg (alone or in combination with aspirin) compared with aspirin alone or clopidogrel (alone or in combination with aspirin) for adult patients with a history of myocardial infarction at least one year ago and high risk of developing a thrombotic event

For Cost-Minimization Analysis (CMA) + BIA + HFI Analysis

7. Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD)

For Model-based CMA + BIA + HFI Analysis

8. Dipeptidyl peptidase-4 (DPP-4) inhibitors compared to sulfonylureas or SGLT2 inhibitors for adult type 2 diabetes mellitus (DM) patients inadequately controlled on metformin monotherapy

HTA topic for ELSHI Assessment

1. Nilotinib compared with Imatinib for adult patients with Philadelphia-positive, chronic myeloid leukemia in chronic phase
   
   Based on the HTA Methods Guide, there are various methodologies for ELSHI assessment. The standard methodology is a scoping review, and additional methodologies, as deemed necessary, may include Qualitative Systematic Review (QSR) or primary data collection methods such as Focus Group Discussions (FGDs) or Key Informant Interviews (KIIs). The determination of whether additional methodologies are needed shall be guided by a review of existing evidence by the proponent.

For interested researchers, kindly take note of the following important dates:

• Deadline of expression of interest: 8 January 2025 (Wednesday)
• Deadline for submission of requirements: 10 working days from the submission of the expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide: